Registry for patients with Hypertrophic Cardiomyopathy in Austria

Austrian Hypertrophic Cardiomyopathy Registry

This study is gathering information from patients with Hypertrophic Cardiomyopathy in Austria to see how their symptoms and genetics can help improve understanding and treatment of the condition.

Quick facts

• Study type: Observational
• Enrollment: 1000 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: Medical University of Graz (Academic / other)
• Locations: 15 sites (Linz, Linz and 14 other locations)
• Trial ID: NCT06368518 on ClinicalTrials.gov

What this trial studies

The Austrian Hypertrophic Cardiomyopathy (HCM) Registry is a prospective, multicenter initiative that enrolls patients from various outpatient clinics across Austria. Participants undergo a structured examination process that includes assessments of symptoms, medical history, and genetic testing, along with clinical data collection through electrocardiograms and echocardiography. The registry aims to standardize clinical assessments and facilitate innovative epidemiological analyses to address gaps in evidence related to HCM. Data collected will be managed through an electronic case report form, allowing for multicenter analyses under the oversight of a steering committee.

Who should consider this trial

Good fit: Ideal candidates include patients with a confirmed diagnosis of Hypertrophic Cardiomyopathy and specific echocardiographic findings.

Not a fit: Patients under 18 years old or those with known cardiac amyloidosis may not benefit from this registry.

Why it matters

Potential benefit: If successful, this registry could improve the understanding and management of Hypertrophic Cardiomyopathy, leading to better patient outcomes.

How similar studies have performed: Other registries focusing on Hypertrophic Cardiomyopathy have shown promise in improving patient care and understanding of the condition.

Eligibility criteria

Inclusion Criteria:

* Patients admitted to the HCM outpatient clinic of participating centers of the HCM Registry
* Interventricular septal thickness ≥ 13 mm and cardiomyopathy-specific red flags OR Interventricular septal thickness ≥ 15 mm not explainable by loading conditions OR Interventricular septal thickness ≥ 17 mm
* Willingness and ability to provide signed informed consent form (ICF) prior to participation in any study-related procedures

Exclusion criteria:

* Age \< 18 years
* Known cardiac amyloidosis

Where this trial is running

Linz, Linz and 14 other locations

• Kepler University Hospital Linz — Linz, Linz, Austria (Recruiting)
• University Hospital St. Pölten — Sankt Pölten, Lower Austria, Austria (Recruiting)
• Hospital Landesklinikum Wiener Neustadt — Wiener Neustadt, Lower Austria, Austria (Recruiting)
• Paracelsus Medical University of Salzburg — Salzburg, State of Salzburg, Austria (Recruiting)
• Clinic Cardinal Schwarzenberg — Schwarzach im Pongau, State of Salzburg, Austria (Recruiting)
• Medical University of Vienna — Vienna, State of Vienna, Austria (Recruiting)
• Favoriten Clinic Vienna — Vienna, State of Vienna, Austria (Active_not_recruiting)
• Klinik Ottakring — Vienna, State of Vienna, Austria (Recruiting)
• Hospital Graz 2 West — Graz, Styria, Austria (Recruiting)
• Medical University of Graz — Graz, Styria, Austria (Recruiting)
• Medical University of Innsbruck — Innsbruck, Tyrol, Austria (Recruiting)
• Hospital St. Josef Braunau — Braunau am Inn, Upper Austria, Austria (Recruiting)
• Ordensklinikum Linz — Linz, Upper Austria, Austria (Recruiting)
• General Hospital St. Johann in Tirol — Sankt Johann in Tirol, Austria (Recruiting)
• Clinic Wels-Grieskirchen — Wels-Grieskirchen, Austria (Recruiting)

Study contacts

• Study coordinator: Nicolas D Verheyen, MD

Conditions Hypertrophic Cardiomyopathy; Left ventricular hypertrophy; Hypertrophic Phenotype